The vitamin D analogue ED71 but not 1,25(OH)2D3 targets HIF1α protein in osteoclasts

Yuiko Sato, Yoshiteru Miyauchi, Shigeyuki Yoshida, Mayu Morita, Tami Kobayashi, Hiroya Kanagawa, Eri Katsuyama, Atsuhiro Fujie, Wu Hao, Toshimi Tando, Ryuichi Watanabe, Kana Miyamoto, Hideo Morioka, Morio Matsumoto, Yoshiaki Toyama, Takeshi Miyamoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Although both an active form of the vitamin D metabolite, 1,25(OH)2D3, and the vitamin D analogue, ED71 have been used to treat osteoporosis, anti-bone resorbing activity is reportedly seen only in ED71-but not in 1,25(OH)2D3 -treated patients. In addition, how ED71 inhibits osteoclast activity in patients has not been fully characterized. Recently, HIF1α expression in osteoclasts was demonstrated to be required for development of post-menopausal osteoporosis. Here we show that ED71 but not 1,25(OH)2D3, suppress HIF1α protein expression in osteoclasts in vitro. We found that 1,25(OH)2D3 or ED71 function in osteoclasts requires the vitamin D receptor (VDR). ED71 was significantly less effective in inhibiting M-CSF and RANKL-stimulated osteoclastogenesis than was 1,25(OH)2D3 in vitro. Downregulation of c-Fos protein and induction of Ifnβ mRNA in osteoclasts, both of which reportedly block osteoclastogenesis induced by 1,25(OH)2D3 in vitro, were both significantly higher following treatment with 1,25(OH)2D3 than with ED71. Thus, suppression of HIF1α protein activity in osteoclasts in vitro, which is more efficiently achieved by ED71 rather than by 1,25(OH)2D3, could be a reliable read-out in either developing or screening reagents targeting osteoporosis.

Original languageEnglish
Article numbere111845
JournalPLoS One
Volume9
Issue number11
DOIs
Publication statusPublished - 2014 Nov 6

Fingerprint

osteoclasts
Osteoclasts
vitamin D
Vitamin D
osteoporosis
Proteins
proteins
Osteogenesis
Osteoporosis
Proto-Oncogene Proteins c-fos
menopause
Calcitriol Receptors
Postmenopausal Osteoporosis
Macrophage Colony-Stimulating Factor
Metabolites
Screening
Down-Regulation
protein synthesis
bones
metabolites

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Sato, Y., Miyauchi, Y., Yoshida, S., Morita, M., Kobayashi, T., Kanagawa, H., ... Miyamoto, T. (2014). The vitamin D analogue ED71 but not 1,25(OH)2D3 targets HIF1α protein in osteoclasts. PLoS One, 9(11), [e111845]. https://doi.org/10.1371/journal.pone.0111845

The vitamin D analogue ED71 but not 1,25(OH)2D3 targets HIF1α protein in osteoclasts. / Sato, Yuiko; Miyauchi, Yoshiteru; Yoshida, Shigeyuki; Morita, Mayu; Kobayashi, Tami; Kanagawa, Hiroya; Katsuyama, Eri; Fujie, Atsuhiro; Hao, Wu; Tando, Toshimi; Watanabe, Ryuichi; Miyamoto, Kana; Morioka, Hideo; Matsumoto, Morio; Toyama, Yoshiaki; Miyamoto, Takeshi.

In: PLoS One, Vol. 9, No. 11, e111845, 06.11.2014.

Research output: Contribution to journalArticle

Sato, Y, Miyauchi, Y, Yoshida, S, Morita, M, Kobayashi, T, Kanagawa, H, Katsuyama, E, Fujie, A, Hao, W, Tando, T, Watanabe, R, Miyamoto, K, Morioka, H, Matsumoto, M, Toyama, Y & Miyamoto, T 2014, 'The vitamin D analogue ED71 but not 1,25(OH)2D3 targets HIF1α protein in osteoclasts', PLoS One, vol. 9, no. 11, e111845. https://doi.org/10.1371/journal.pone.0111845
Sato Y, Miyauchi Y, Yoshida S, Morita M, Kobayashi T, Kanagawa H et al. The vitamin D analogue ED71 but not 1,25(OH)2D3 targets HIF1α protein in osteoclasts. PLoS One. 2014 Nov 6;9(11). e111845. https://doi.org/10.1371/journal.pone.0111845
Sato, Yuiko ; Miyauchi, Yoshiteru ; Yoshida, Shigeyuki ; Morita, Mayu ; Kobayashi, Tami ; Kanagawa, Hiroya ; Katsuyama, Eri ; Fujie, Atsuhiro ; Hao, Wu ; Tando, Toshimi ; Watanabe, Ryuichi ; Miyamoto, Kana ; Morioka, Hideo ; Matsumoto, Morio ; Toyama, Yoshiaki ; Miyamoto, Takeshi. / The vitamin D analogue ED71 but not 1,25(OH)2D3 targets HIF1α protein in osteoclasts. In: PLoS One. 2014 ; Vol. 9, No. 11.
@article{686ed0831ccc4263acfc672b4b2b7aa3,
title = "The vitamin D analogue ED71 but not 1,25(OH)2D3 targets HIF1α protein in osteoclasts",
abstract = "Although both an active form of the vitamin D metabolite, 1,25(OH)2D3, and the vitamin D analogue, ED71 have been used to treat osteoporosis, anti-bone resorbing activity is reportedly seen only in ED71-but not in 1,25(OH)2D3 -treated patients. In addition, how ED71 inhibits osteoclast activity in patients has not been fully characterized. Recently, HIF1α expression in osteoclasts was demonstrated to be required for development of post-menopausal osteoporosis. Here we show that ED71 but not 1,25(OH)2D3, suppress HIF1α protein expression in osteoclasts in vitro. We found that 1,25(OH)2D3 or ED71 function in osteoclasts requires the vitamin D receptor (VDR). ED71 was significantly less effective in inhibiting M-CSF and RANKL-stimulated osteoclastogenesis than was 1,25(OH)2D3 in vitro. Downregulation of c-Fos protein and induction of Ifnβ mRNA in osteoclasts, both of which reportedly block osteoclastogenesis induced by 1,25(OH)2D3 in vitro, were both significantly higher following treatment with 1,25(OH)2D3 than with ED71. Thus, suppression of HIF1α protein activity in osteoclasts in vitro, which is more efficiently achieved by ED71 rather than by 1,25(OH)2D3, could be a reliable read-out in either developing or screening reagents targeting osteoporosis.",
author = "Yuiko Sato and Yoshiteru Miyauchi and Shigeyuki Yoshida and Mayu Morita and Tami Kobayashi and Hiroya Kanagawa and Eri Katsuyama and Atsuhiro Fujie and Wu Hao and Toshimi Tando and Ryuichi Watanabe and Kana Miyamoto and Hideo Morioka and Morio Matsumoto and Yoshiaki Toyama and Takeshi Miyamoto",
year = "2014",
month = "11",
day = "6",
doi = "10.1371/journal.pone.0111845",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - The vitamin D analogue ED71 but not 1,25(OH)2D3 targets HIF1α protein in osteoclasts

AU - Sato, Yuiko

AU - Miyauchi, Yoshiteru

AU - Yoshida, Shigeyuki

AU - Morita, Mayu

AU - Kobayashi, Tami

AU - Kanagawa, Hiroya

AU - Katsuyama, Eri

AU - Fujie, Atsuhiro

AU - Hao, Wu

AU - Tando, Toshimi

AU - Watanabe, Ryuichi

AU - Miyamoto, Kana

AU - Morioka, Hideo

AU - Matsumoto, Morio

AU - Toyama, Yoshiaki

AU - Miyamoto, Takeshi

PY - 2014/11/6

Y1 - 2014/11/6

N2 - Although both an active form of the vitamin D metabolite, 1,25(OH)2D3, and the vitamin D analogue, ED71 have been used to treat osteoporosis, anti-bone resorbing activity is reportedly seen only in ED71-but not in 1,25(OH)2D3 -treated patients. In addition, how ED71 inhibits osteoclast activity in patients has not been fully characterized. Recently, HIF1α expression in osteoclasts was demonstrated to be required for development of post-menopausal osteoporosis. Here we show that ED71 but not 1,25(OH)2D3, suppress HIF1α protein expression in osteoclasts in vitro. We found that 1,25(OH)2D3 or ED71 function in osteoclasts requires the vitamin D receptor (VDR). ED71 was significantly less effective in inhibiting M-CSF and RANKL-stimulated osteoclastogenesis than was 1,25(OH)2D3 in vitro. Downregulation of c-Fos protein and induction of Ifnβ mRNA in osteoclasts, both of which reportedly block osteoclastogenesis induced by 1,25(OH)2D3 in vitro, were both significantly higher following treatment with 1,25(OH)2D3 than with ED71. Thus, suppression of HIF1α protein activity in osteoclasts in vitro, which is more efficiently achieved by ED71 rather than by 1,25(OH)2D3, could be a reliable read-out in either developing or screening reagents targeting osteoporosis.

AB - Although both an active form of the vitamin D metabolite, 1,25(OH)2D3, and the vitamin D analogue, ED71 have been used to treat osteoporosis, anti-bone resorbing activity is reportedly seen only in ED71-but not in 1,25(OH)2D3 -treated patients. In addition, how ED71 inhibits osteoclast activity in patients has not been fully characterized. Recently, HIF1α expression in osteoclasts was demonstrated to be required for development of post-menopausal osteoporosis. Here we show that ED71 but not 1,25(OH)2D3, suppress HIF1α protein expression in osteoclasts in vitro. We found that 1,25(OH)2D3 or ED71 function in osteoclasts requires the vitamin D receptor (VDR). ED71 was significantly less effective in inhibiting M-CSF and RANKL-stimulated osteoclastogenesis than was 1,25(OH)2D3 in vitro. Downregulation of c-Fos protein and induction of Ifnβ mRNA in osteoclasts, both of which reportedly block osteoclastogenesis induced by 1,25(OH)2D3 in vitro, were both significantly higher following treatment with 1,25(OH)2D3 than with ED71. Thus, suppression of HIF1α protein activity in osteoclasts in vitro, which is more efficiently achieved by ED71 rather than by 1,25(OH)2D3, could be a reliable read-out in either developing or screening reagents targeting osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=84910613696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910613696&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0111845

DO - 10.1371/journal.pone.0111845

M3 - Article

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e111845

ER -